Fig. 5

Clinical and imaging outcomes. a Expanded disability status scores (EDSS), measured every 6 months. b Number of new T2 lesions. c T2 volume. d Number of Gd+ lesions at baseline; subsequent timepoints represent new Gd+ lesions. e Brain parenchymal fraction (BPF). Data are expressed as median/IQR values for all patients at each timepoint. p values indicate significant changes from baseline (M0), where applicable, as follows: **p ≤ 0.01, *p ≤ 0.05; Kruskal-Wallis test for EDSS, number of new T2 and Gd+ lesions, and mixed effects ANOVA with Tukey’s corrections for T2 volume and BPF. f Number of patients with new T2 lesions in the first year (up to M12), second year (M13–M24), third year (M25–M36), and fourth year (M37–M48) accompanied by total number for all timepoints on study. g Total number of new lesions in each year. h Number of patients with Gd+ lesions at M0 [11] and new Gd+ lesions in each year, accompanied by the total number of new Gd+ lesions from M12 to M48. i Total number Gd+ lesions at M0 and new Gd+ lesions in each year. j Number of patients who experienced relapses in each year on study, accompanied by the total for all years. k Number of patients who experienced relapses and/or new Gd+ lesions (active disease) or had no relapses or Gd+ lesions (stable disease) on study